Does tacrolimus increase susceptibility to infections and delay wound healing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Tacrolimus Increase Infection Risk and Impair Wound Healing?

Yes, tacrolimus increases susceptibility to infections and can impair wound healing, though the effects differ significantly between systemic (oral/IV) and topical formulations.

Infection Risk

Systemic Tacrolimus (Oral/IV)

Patients receiving systemic tacrolimus are at definitively increased risk for bacterial, viral, fungal, and protozoal infections, including life-threatening opportunistic infections 1. The FDA drug label explicitly warns that immunosuppressants including tacrolimus increase infection risk, which may lead to fatal outcomes 1.

The infection risk profile includes:

  • Bacterial infections: Most common in early post-transplant period, particularly nosocomial pathogens 2, 3
  • Opportunistic infections: Including polyomavirus-associated nephropathy (PVAN/BK virus), JC virus-associated progressive multifocal leukoencephalopathy (PML), and cytomegalovirus (CMV) 1
  • Fungal infections: Mortality rates up to 50% in certain fungal infections 3
  • Severe infections requiring IV therapy: Incidence of 37% in heart transplant recipients on tacrolimus versus 12% with cyclosporine 2

The mechanism involves immunosuppression through decreased immunoglobulin production (IgG, free light chains, heavy/light chain pairs), with higher tacrolimus exposure correlating with greater immunoglobulin suppression 4.

Critical caveat: Recent evidence in systemic lupus erythematosus patients shows tacrolimus may actually reduce infection risk by 60% compared to other conventional immunosuppressants like cyclophosphamide or mycophenolate mofetil 5. This suggests tacrolimus may be relatively safer than alternative immunosuppressants in certain contexts, though transplant patients remain at elevated baseline risk.

Topical Tacrolimus

For topical formulations used in atopic dermatitis, the infection risk is theoretical rather than proven 6. Guidelines note that topical tacrolimus can increase prevalence of local viral infections while decreasing Staphylococcus aureus colonization, but evidence supporting these risks is inconsistent 7. Systemic absorption after topical application is negligible, and routine blood monitoring is not recommended 7.

Wound Healing Effects

Systemic Tacrolimus

The evidence on wound healing is contradictory and depends on the clinical context:

Animal studies demonstrate impaired healing: Systemic tacrolimus at 2.0 mg/kg/day reduced wound-breaking strength and collagen deposition in rats, paralleled by decreased nitric oxide synthesis—a critical mediator of wound healing 8. Tacrolimus accumulates in wound fluid at approximately 10-fold higher concentrations than blood levels 8.

Human surgical data shows no negative impact: In Crohn's disease patients undergoing intestinal resection, perioperative IV tacrolimus (median 1 mg/day for 11 days) showed no significant correlation with postoperative infectious complications in both simple and multiple regression analyses 9. This suggests that in real-world surgical practice, tacrolimus may be safely used perioperatively.

Orthopaedic surgery concerns: Transplant medications including tacrolimus compromise wound healing by inhibiting inflammatory responses, decreasing collagen synthesis, reducing angiogenesis, and impairing cellular proliferation, leading to elevated risks of surgical site infections, wound dehiscence, and delayed union 10.

Topical Tacrolimus

Topical tacrolimus does not impair acute wound healing 11. In a murine full-thickness wound model, topical tacrolimus showed re-epithelialization and inflammatory cell infiltration patterns similar to vehicle control, unlike topical corticosteroids which significantly delayed healing 11.

Clinical Recommendations

For Systemic Tacrolimus Users:

  1. Monitor closely for infections: Particularly bacterial infections in early post-transplant period (first year), with aggressive diagnostic and therapeutic approaches 2, 3
  2. CMV prophylaxis: Essential for CMV seronegative recipients receiving organs from CMV seropositive donors 1
  3. EBV monitoring: Check serology during treatment due to post-transplant lymphoproliferative disorder risk 1
  4. Perioperative management: Based on current evidence, tacrolimus can be continued perioperatively in selected patients (e.g., inflammatory bowel disease surgery) without increased wound complications 9, though orthopaedic procedures may warrant more caution 10
  5. Dose optimization: Lower doses (≤2 mg/day) and combination with hydroxychloroquine may reduce infection risk in appropriate patients 5

For Topical Tacrolimus Users:

  1. No special wound healing precautions needed: Topical formulation does not impair acute wound healing 11
  2. Counsel on local reactions: Burning, stinging, and pruritus are common in the first week but do not indicate impaired healing 7
  3. Avoid in compromised skin barriers: Do not use in conditions like Netherton syndrome where systemic absorption could occur 6

Key Pitfall to Avoid:

Do not extrapolate topical tacrolimus data to systemic use or vice versa—these are fundamentally different exposures with distinct risk profiles. The negligible systemic absorption from topical application means infection and wound healing concerns are primarily relevant only for oral/IV formulations 7.

References

Research

Transplant Medications and Their Effects on Wound Healing in Orthopaedic Surgery.

The Journal of the American Academy of Orthopaedic Surgeons, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.